Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 12/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3007871 | 0.95 | CTSS (0.37) | CTSSRAB9ASMN1; SMN2KMT2ANR3C1 | |
| SCHEMBL3019472 | 0.94 | CTSS (0.36) | CTSSRAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3012897 | 0.94 | CTSS (0.36) | CTSSKMT2A | |
| SCHEMBL3012276 | 0.93 | CTSS (0.47) | CTSSRAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3012034 | 0.93 | CTSS (0.43) | CTSSRAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3012960 | 0.92 | LMNA (0.36) | CTSSRAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3004553 | 0.92 | MAPT (0.40) | CTSSSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3002528 | 0.92 | CTSS (0.35) | CTSSRAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3013818 | 0.91 | MAPT (0.36) | CTSSRAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3012307 | 0.90 | CTSS (0.42) | CTSSRAB9ASMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | CTSS 106/4885RAB9A 2943/4885SMN1; SMN2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.